Skip to main content
. 2020 Apr 28;10:7163. doi: 10.1038/s41598-020-64145-7

Figure 5.

Figure 5

In vivo bactericidal activity of colistin in combination with endolysins ElyA1 and ElyA2. (a) Survival curves for G. mellonella larvae infected with A. baumannii clinical strain GMA001 and treated with colistin (1/4 MIC) and with colistin (1/4 MIC) combined with endolysin ElyA1 (25 μg/ml). Survival curves for G. mellonella larvae infected with A. baumannii clinical strain GMA001 and treated with colistin (1/4 MIC) or with colistin (1/4 MIC) combined with endolysin ElyA2 (25 μg/ml). This experiment was carried out with an appropriate survival control. *Statistically significant differences (p < 0.05) were determined by Graham-Breslow-Wilcoxon test (GraphPad Prism v.6); (b) Antimicrobial activity of endolysin ElyA1 in a murine skin model. CFU quantification in homogenized mouse skin after infection with A. baumannii GMA001 and treatment with colistin (1/4 MIC) in combination with different doses of endolysin ElyA1 (50 µg and 350 µg) or with buffer or colistin (controls). (c) Antimicrobial activity of ElyA1 in a murine lung infection model. CFU quantification in lungs after infection with A. baumannii GMA001 and treatment post-infection with colistin in combination with350 µg of ElyA1. * Statistically significant differences (p < 0.05) were determined by t-Student test (GraphPad Prism v.6).